COMIRNATY Omicron XBB.1.5 (Omicron XBB.1.5-adapted monovalent COVID-19 vaccine) / BioNTech, Pfizer - LARVOL DELTA

Protection conferred by the Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccine to patients hospitalized with COVID-19 in Greece in 2023-2024. (PubMed, Infect Dis Now) - "In comparison with unvaccinated individuals, the Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccine conferred significant protection against in-hospital mortality and reduced length of stay to COVID-19 patients hospitalized in Greece during the 2023-2024 season."

Journal • Critical care • Infectious Disease • Novel Coronavirus Disease

Immunogenicity of the Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in patients with cirrhosis. (PubMed, Scand J Gastroenterol) - " A fifth mRNA-based COVID-19 booster dose significantly augments both humoral and cellular immunity in patients with liver cirrhosis. These findings support the use of a single annual booster dose to maintain adequate immune protection in this vulnerable population."

Journal • Fibrosis • Gastroenterology • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Novel Coronavirus Disease • IL2

Understanding the Effectiveness of the Comirnaty Monovalent and Bivalent Vaccines During the Winter Coronavirus (COVID-19) Infection Survey. (PubMed, J Infect) - "These findings provide important insights into the effectiveness of targeted vaccine strategies in the context of an evolving pandemic. As SARS-CoV-2 continues to mutate, adaptive approaches in vaccine design and public health policy will be key to addressing emerging variants and protecting high-risk groups."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation. (PubMed, Sci Rep) - "In a population of long-term allo-HSCT survivors, the majority of whom had a prior confirmed COVID-19 infection, both pre- and post-booster immune responses were robust. However, patients undergoing immunosuppressive treatment for GvHD exhibited significantly weaker responses."

Journal • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Novel Coronavirus Disease • Transplantation

Neutralization activity of HCWs' sera after Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccination. (PubMed, J Infect) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Andusomeran and raxtozinameran for prevention of COVID-19 disease. (PubMed, Aust Prescr) - No abstract available

Journal • Review • Infectious Disease • Novel Coronavirus Disease

I-SPARC: COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 (clinicaltrials.gov) - P4 | N=152 | Terminated | Sponsor: Jules Bordet Institute | N=440 ➔ 152 | Trial completion date: Dec 2024 ➔ Jan 2024 | Recruiting ➔ Terminated; The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years.

Enrollment change • Trial completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases

COVID-19 Vaccines in Children. (PubMed, J Clin Med) - "Recently, recommendations for COVID-19 vaccination were updated accordingly to the 2023-2024 Omicron-XBB.1.5-adapted monovalent COVID-19 vaccine to provide heightened protection against currently circulating SARS-CoV-2 XBB-sublineage variants. COVID-19 vaccines have proven to be safe, efficacious, and effective at protecting against COVID-19 and preventing severe illness in children and adolescents."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Respiratory Diseases

I-SPARC: COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 (clinicaltrials.gov) - P4 | N=440 | Recruiting | Sponsor: Jules Bordet Institute

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union (GlobeNewswire) - "Pfizer Inc...and BioNTech SE...announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) administered as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history....The CHMP’s recommendation is based on the full body of previous clinical, non-clinical, and real-world evidence supporting the safety and efficacy of the COVID-19 vaccines by Pfizer and BioNTech."

European regulatory • Infectious Disease • Novel Coronavirus Disease